Enanta Historical Income Statement

ENTA Stock

USD 13.91 0.35 2.58%

Historical analysis of Enanta Pharmaceuticals income statement accounts such as Selling General Administrative of 63.9 M or Total Revenue of 104.9 M can show how well Enanta Pharmaceuticals performed in making a profits. Evaluating Enanta Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Enanta Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Enanta Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Enanta Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.

About Enanta Income Statement Analysis

Enanta Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Enanta Pharmaceuticals shareholders. The income statement also shows Enanta investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Enanta Pharmaceuticals Income Statement Chart

Enanta Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Enanta's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Enanta Pharmaceuticals revenue and expense. Enanta Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.

At present, Enanta Pharmaceuticals' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 104.9 M, whereas Depreciation And Amortization is forecasted to decline to about 1.9 M.

Selling General Administrative Total Revenue Gross Profit Other Operating Expenses Cost Of Revenue

Total Revenue

Total revenue comprises all receipts Enanta Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Enanta Pharmaceuticals minus its cost of goods sold. It is profit before Enanta Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Enanta Pharmaceuticals. It is also known as Enanta Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Cost Of Revenue

Cost of Revenue is found on Enanta Pharmaceuticals income statement and represents the costs associated with goods and services Enanta Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most accounts from Enanta Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Enanta Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.At present, Enanta Pharmaceuticals' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 104.9 M, whereas Depreciation And Amortization is forecasted to decline to about 1.9 M.

	2021	2022	2023	2024 (projected)
Gross Profit	83.2M	76.8M	88.4M	104.5M
Total Revenue	86.2M	79.2M	91.1M	104.9M

Gross Profit Total Revenue

Enanta Pharmaceuticals income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Cost Of Revenue	Net Income From Continuing Ops	Non Operating Income Net Other	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation	Extraordinary Items
Depreciation And Amortization		0.83	0.62	0.56	0.55	0.79	-0.46	-0.47	0.82	-0.46	0.79	-0.44	0.7	-0.45	-0.21	-0.15	-0.44	-0.35	-0.91	0.47	0.64	0.82	0.17
Interest Expense	0.83		0.48	0.55	0.55	0.67	-0.33	-0.33	0.71	-0.32	0.67	-0.31	0.83	-0.3	-0.2	-0.3	-0.29	-0.58	-0.65	0.61	0.87	0.83	0.21
Selling General Administrative	0.62	0.48		0.2	0.18	0.95	-0.79	-0.78	0.92	-0.77	0.95	-0.78	0.7	-0.84	-0.11	-0.38	-0.83	-0.45	-0.7	0.83	0.55	0.54	0.67
Total Revenue	0.56	0.55	0.2		1.0	0.32	0.33	0.33	0.34	0.34	0.32	0.35	0.58	0.29	0.45	0.35	0.3	-0.11	-0.36	0.29	0.56	0.42	-0.02
Gross Profit	0.55	0.55	0.18	1.0		0.3	0.34	0.34	0.33	0.36	0.3	0.36	0.57	0.3	0.45	0.36	0.31	-0.1	-0.35	0.28	0.55	0.41	-0.03
Other Operating Expenses	0.79	0.67	0.95	0.32	0.3		-0.79	-0.78	1.0	-0.77	1.0	-0.77	0.76	-0.8	-0.25	-0.43	-0.79	-0.56	-0.84	0.78	0.62	0.75	0.55
Operating Income	-0.46	-0.33	-0.79	0.33	0.34	-0.79		1.0	-0.77	1.0	-0.79	1.0	-0.36	0.99	0.57	0.65	0.98	0.5	0.64	-0.54	-0.25	-0.5	-0.47
Ebit	-0.47	-0.33	-0.78	0.33	0.34	-0.78	1.0		-0.77	1.0	-0.78	1.0	-0.34	0.98	0.59	0.66	0.98	0.49	0.64	-0.51	-0.23	-0.51	-0.45
Research Development	0.82	0.71	0.92	0.34	0.33	1.0	-0.77	-0.77		-0.76	1.0	-0.76	0.76	-0.78	-0.28	-0.43	-0.77	-0.58	-0.86	0.75	0.63	0.79	0.51
Ebitda	-0.46	-0.32	-0.77	0.34	0.36	-0.77	1.0	1.0	-0.76		-0.77	1.0	-0.33	0.98	0.59	0.66	0.98	0.49	0.63	-0.51	-0.23	-0.5	-0.45
Total Operating Expenses	0.79	0.67	0.95	0.32	0.3	1.0	-0.79	-0.78	1.0	-0.77		-0.77	0.76	-0.8	-0.25	-0.43	-0.79	-0.56	-0.84	0.78	0.62	0.75	0.55
Income Before Tax	-0.44	-0.31	-0.78	0.35	0.36	-0.77	1.0	1.0	-0.76	1.0	-0.77		-0.33	0.98	0.58	0.65	0.98	0.49	0.62	-0.52	-0.22	-0.48	-0.46
Total Other Income Expense Net	0.7	0.83	0.7	0.58	0.57	0.76	-0.36	-0.34	0.76	-0.33	0.76	-0.33		-0.37	0.03	-0.23	-0.36	-0.43	-0.58	0.9	0.95	0.65	0.49
Net Income	-0.45	-0.3	-0.84	0.29	0.3	-0.8	0.99	0.98	-0.78	0.98	-0.8	0.98	-0.37		0.43	0.62	1.0	0.45	0.61	-0.57	-0.25	-0.45	-0.51
Income Tax Expense	-0.21	-0.2	-0.11	0.45	0.45	-0.25	0.57	0.59	-0.28	0.59	-0.25	0.58	0.03	0.43		0.47	0.43	0.42	0.38	-0.02	0.0	-0.36	-0.02
Cost Of Revenue	-0.15	-0.3	-0.38	0.35	0.36	-0.43	0.65	0.66	-0.43	0.66	-0.43	0.65	-0.23	0.62	0.47		0.63	0.46	0.26	-0.34	-0.22	-0.47	-0.27
Net Income From Continuing Ops	-0.44	-0.29	-0.83	0.3	0.31	-0.79	0.98	0.98	-0.77	0.98	-0.79	0.98	-0.36	1.0	0.43	0.63		0.45	0.6	-0.57	-0.24	-0.45	-0.51
Non Operating Income Net Other	-0.35	-0.58	-0.45	-0.11	-0.1	-0.56	0.5	0.49	-0.58	0.49	-0.56	0.49	-0.43	0.45	0.42	0.46	0.45		0.27	-0.44	-0.45	-0.58	-0.25
Tax Provision	-0.91	-0.65	-0.7	-0.36	-0.35	-0.84	0.64	0.64	-0.86	0.63	-0.84	0.62	-0.58	0.61	0.38	0.26	0.6	0.27		-0.47	-0.47	-0.76	-0.23
Interest Income	0.47	0.61	0.83	0.29	0.28	0.78	-0.54	-0.51	0.75	-0.51	0.78	-0.52	0.9	-0.57	-0.02	-0.34	-0.57	-0.44	-0.47		0.83	0.46	0.7
Net Interest Income	0.64	0.87	0.55	0.56	0.55	0.62	-0.25	-0.23	0.63	-0.23	0.62	-0.22	0.95	-0.25	0.0	-0.22	-0.24	-0.45	-0.47	0.83		0.57	0.41
Reconciled Depreciation	0.82	0.83	0.54	0.42	0.41	0.75	-0.5	-0.51	0.79	-0.5	0.75	-0.48	0.65	-0.45	-0.36	-0.47	-0.45	-0.58	-0.76	0.46	0.57		0.21
Extraordinary Items	0.17	0.21	0.67	-0.02	-0.03	0.55	-0.47	-0.45	0.51	-0.45	0.55	-0.46	0.49	-0.51	-0.02	-0.27	-0.51	-0.25	-0.23	0.7	0.41	0.21

Click cells to compare fundamentals

Enanta Pharmaceuticals Account Relationship Matchups

Enanta Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	3.6M	3.3M	2.9M	2.4M	2.7M	1.9M
Interest Expense	10.3M	5.3M	1.6M	5.1M	5.9M	3.1M
Selling General Administrative	27.4M	32.5M	45.5M	52.9M	60.8M	63.9M
Total Revenue	122.5M	97.1M	86.2M	79.2M	91.1M	104.9M
Gross Profit	122.5M	97.1M	83.2M	76.8M	88.4M	104.5M
Other Operating Expenses	164.1M	206.6M	210.0M	216.4M	248.9M	261.3M
Operating Income	(41.6M)	(109.6M)	(123.8M)	(137.2M)	(123.5M)	(117.3M)
Ebit	(41.6M)	(109.6M)	(123.8M)	(125.8M)	(113.3M)	(107.6M)
Research Development	136.8M	174.1M	164.5M	163.5M	188.1M	197.5M
Ebitda	(38.0M)	(106.2M)	(121.0M)	(123.5M)	(111.1M)	(105.6M)
Total Operating Expenses	164.1M	206.6M	210.0M	216.4M	248.9M	261.3M
Income Before Tax	(35.0M)	(107.6M)	(122.2M)	(131.0M)	(117.9M)	(112.0M)
Total Other Income Expense Net	6.6M	2.0M	1.7M	6.2M	7.1M	7.5M
Net Income	(36.2M)	(79.0M)	(121.8M)	(133.8M)	(120.4M)	(114.4M)
Income Tax Expense	1.1M	(28.6M)	(433K)	2.8M	2.5M	3.0M
Net Income Applicable To Common Shares	46.4M	(36.2M)	(79.0M)	(121.8M)	(109.6M)	(104.1M)
Net Income From Continuing Ops	(36.2M)	(79.0M)	(121.8M)	(133.8M)	(120.4M)	(114.4M)
Tax Provision	1.1M	(28.6M)	(433K)	2.8M	2.5M	2.4M
Interest Income	6.5M	2.0M	1.6M	11.4M	13.1M	13.7M
Net Interest Income	6.5M	2.0M	1.6M	6.2M	7.1M	4.7M
Reconciled Depreciation	3.6M	3.3M	3.0M	2.4M	2.7M	3.2M

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Enanta Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Enanta Pharmaceuticals' short interest history, or implied volatility extrapolated from Enanta Pharmaceuticals options trading.

Pair Trading with Enanta Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enanta Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enanta Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Enanta Stock

0.71	VKTX	Viking Therapeutics	Pair Corr
0.7	DYAI	Dyadic International Financial Report 8th of May 2024	Pair Corr

Moving against Enanta Stock

0.52	OVID	Ovid Therapeutics	Pair Corr
0.43	LFCR	Lifecore Biomedical Financial Report 6th of June 2024	Pair Corr
0.42	ORGO	Organogenesis Holdings Earnings Call This Week	Pair Corr
0.41	GNLX	Genelux Common	Pair Corr

The ability to find closely correlated positions to Enanta Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enanta Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enanta Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enanta Pharmaceuticals to buy it.

The correlation of Enanta Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enanta Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enanta Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Enanta Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Enanta Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enanta Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enanta Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enanta Pharmaceuticals Stock:

How To Invest In Enanta

Details

Is Enanta Stock a good investment?

Details

What is Enanta Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.

You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Complementary Tools for Enanta Stock analysis

When running Enanta Pharmaceuticals' price analysis, check to measure Enanta Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enanta Pharmaceuticals is operating at the current time. Most of Enanta Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Enanta Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enanta Pharmaceuticals' price. Additionally, you may evaluate how the addition of Enanta Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Fundamental Analysis View fundamental data based on most recent published financial statements
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Global Correlations Find global opportunities by holding instruments from different markets
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum

Is Enanta Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.66)

Earnings Share

(6.57)

Revenue Per Share

3.5

Quarterly Revenue Growth

(0.24)

Return On Assets

(0.23)

The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Enanta Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enanta Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enanta Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Enanta Historical Income Statement

About Enanta Income Statement Analysis

Enanta Pharmaceuticals Income Statement Chart

Total Revenue

Gross Profit

Other Operating Expenses

Cost Of Revenue

Enanta Pharmaceuticals income statement Correlations

Enanta Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Enanta Pharmaceuticals income statement Accounts

Pair Trading with Enanta Pharmaceuticals

Moving together with Enanta Stock

Moving against Enanta Stock

Complementary Tools for Enanta Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income

Tax Provision	- 0.91	Depreciation And Amortization
Tax Provision	- 0.86	Research Development
Tax Provision	- 0.84	Total Operating Expenses
Tax Provision	- 0.84	Other Operating Expenses
Net Income	- 0.84	Selling General Administrative
Net Income From Continuing Ops	- 0.83	Selling General Administrative